# A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma

> **NCT01998893** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 38 (actual)

## Conditions studied

- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]

## Key facts

- **NCT ID:** NCT01998893
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-01
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2014-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01998893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01998893, "A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01998893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*